New combo aims to clear lung cancer DNA in maintenance therapy
NCT ID NCT07264673
First seen Jan 09, 2026 · Last updated May 25, 2026 · Updated 19 times
Summary
This study tests whether adding an immune-boosting vaccine (OSE2101) to a standard immunotherapy (cemiplimab) can better clear cancer DNA from the blood of people with advanced non-small cell lung cancer. About 160 participants who have not worsened after initial chemo-immunotherapy will receive either the combination or standard care as maintenance. The goal is to see if the combo increases the rate of undetectable tumor DNA, which may indicate better disease control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituti Fisioterapici Ospitalieri- Ifo - Istituto Regina Elena
RECRUITINGRoma, RM, 00144, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.